|
|
||||||||
From the Department of Obstetrics and Gynecology (Drs. R. Kaaja, Matila, and Hiilesmaa, and E. Kaaja), Helsinki University Central Hospital, and Division of Pharmacology and Toxicology (E. Kaaja), Department of Pharmacy, University of Helsinki, Finland.
Address correspondence and reprint requests to Dr. V. Hiilesmaa, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Box 140, 00029 HYKS, Finland; e-mail: ville.hiilesmaa{at}hus.fi
Background: Case reports suggest that maternal hepatic enzyme-inducing antiepileptic drugs (AED) increase the risk for neonatal bleeding. Antenatal administration of vitamin K1 to mothers using these drugs therefore is widely recommended. There are, however, no studies on the incidence of this complication.
Objective: To assess the occurrence of bleeding complications in newborns exposed to maternal enzyme-inducing AED in utero.
Methods: The authors prospectively followed 662 pregnancies in women with epilepsy who used enzyme-inducing AED. Of the 667 neonates, 463 were exposed to carbamazepine, 212 to phenytoin, 44 to phenobarbital, 11 to primidone, and 7 to oxcarbazepine. The control subjects were 1,324 nonepileptic pregnancies (1,334 neonates) matched for maternal age, parity, number of fetuses, and delivery date. None of the mothers received vitamin K1 during pregnancy, but all infants received 1 mg vitamin K1 intramuscularly at birth.
Results: A bleeding complication was observed in five (0.7%) of the offspring exposed to maternal enzyme-inducing AED and in five (0.4%) control subjects (p = 0.3). After logistic regression analysis was performed, bleeding was associated with birth at <32 weeks of gestation (adjusted OR = 13; 95% CI = 2.7 to 64) and alcohol abuse (adjusted OR = 17; 95% CI = 1.8 to 162) but not with exposure to enzyme-inducing AED (adjusted OR = 1.1; 95% CI = 0.3 to 4.6; p = 0.8).
Conclusions: These data do not support the hypothesis that maternal enzyme-inducing AED increase the risk for bleeding in the offspring. Antenatal administration of vitamin K to these mothers may still be needed in selected cases.
This article has been cited by other articles:
![]() |
C. L. Harden, P. B. Pennell, B. S. Koppel, C. A. Hovinga, B. Gidal, K. J. Meador, J. Hopp, T. Y. Ting, W. A. Hauser, D. Thurman, et al. Practice Parameter update: Management issues for women with epilepsy--Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society Neurology, July 14, 2009; 73(2): 142 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
M D O'Brien and S K Gilmour-White Management of epilepsy in women Postgrad. Med. J., May 1, 2005; 81(955): 278 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Hey Vitamin K--what, why, and when Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2003; 88(2): F80 - F83. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yoshikawa, S. Yamazaki, T. Watanabe, and T. Abe Vitamin K Deficiency in Severely Disabled Children J Child Neurol, February 1, 2003; 18(2): 93 - 97. [Abstract] [PDF] |
||||
![]() |
Antiepileptic Drugs and Neonatal Bleeding Journal Watch Psychiatry, August 21, 2002; 2002(821): 11 - 11. [Full Text] |
||||
![]() |
Antiepileptic Drugs and Neonatal Bleeding Journal Watch Neurology, June 27, 2002; 2002(627): 6 - 6. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |